A phase 1 trial has reported positive safety findings of SON-1010 among patients with advanced leiomyosarcoma (LMS) or liposarcoma (LPS). A clinical trial has reported positive safety findings of ...

or liposarcoma (LPS). The expansion cohort builds on the successful completion of monotherapy dose escalation and assignment of the SON-1010 maximum tolerated (MTD) dose of 1200 ng/kg ...